Investigators in the phase 3 BENEFIT study evaluated MRD negativity at 12 and 24 months in patients with newly diagnosed multiple myeloma (NDMM) transplant-ineligible (TI) patients.

Johnson & Johnson seeks FDA approval for Darzalex Faspro-based regimen (D-VRd) for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. Phase 3 CEPHEUS study shows D-VRd ...

Today, there are more highly effective options for the treatment of newly diagnosed multiple myeloma than ever before, and more are on the way. Novel drug regimens, autologous stem cell transplant ...

Results showed treatment with D-VRd reduced the risk of disease progression or death by 60% compared with VRd alone. The Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab ...

Isatuximab with VRd significantly improves progression-free survival in newly diagnosed multiple myeloma patients ineligible for stem cell transplant. The IMROZ trial demonstrated a 40% reduction in ...

The CEPHEUS trial is a trial for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplantation, or in whom a transplant was deferred. And 395 patients were randomized ...

In the phase 3 COBRA trial, the carfilzomib/lenalidomide/dexamethasone regimen shows significant improvements in PFS and ...

Surbhi Sidana, MD, MBBS, shares how the addition of an anti-CD38 antibody to the VRd regimen significantly improves progression-free survival for patients with transplant-ineligible multiple myeloma.

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma last week, J&J has wasted little time hitting back with new data on its own ...

A four-drug regimen offers superior disease control and response depth in multiple myeloma compared to three-drug regimens. Adding monoclonal antibodies like Darzalex to standard treatments improves ...

Please provide your email address to receive an email when new articles are posted on . The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or ...